Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis („ProDERM Study“) - Aggarwal, R; Charles-Schoeman, C; Schessl, J (Medicine (Baltimore), 2021)